Saturday, 02 August 2025

Canadian Government Funds Development Of Inhaled COVID-19 Vaccine

100 Percent Fed Up
Hits: 89

Researchers at McMaster University have started a phase 2 clinical trial of an inhaled COVID-19 vaccine.

The AeroVax inhaled COVID-19 vaccine trial recently received an $8 million boost from the Canadian Institutes of Health Research (CIHR).

WATCH:

Per AeroVax:

This new vaccine, named ChAd-triCoV/Mac, targets three different proteins in the SARS CoV-2 virus to improve the vaccine’s ability to protect against new strains (or variants) of the COVID virus.

The AeroVax Trial is a Phase 2 clinical trial funded by the Canadian Institutes of Health Research (CIHR), Canada’s federal funding agency for health research.

The AeroVax Trial will evaluate if this new COVID-19 vaccine is safe to give by aerosol (inhalation) to people who have been vaccinated with at least three doses of a COVID mRNA vaccine. The researchers also want to look at how the body’s immune system responds to this vaccine. Participants will be randomly assigned to receive either the vaccine or a placebo.

A placebo is an inactive substance that doesn’t have any therapeutic effect. Placebos are used by researchers to compare to an active substance to see if the active substance is having any effect or causing any side effects.

McMaster University has also received funding from the Gates Foundation.

“To find new lead molecules against infectious diseases that disproportionately affect the populations in LIMCs,” a grant from October 2023 read.

The grant was worth nearly $500,000.

Per News-Medical:

The new vaccine is entirely Canadian, from design and biomanufacturing at McMaster’s Robert E. Fitzhenry Vector Laboratory to pre-clinical and clinical testing conducted by a team of Canadian experts, with Canadian participants, at Canadian research sites.

For the new trial, researchers hope to include 350 participants from across Canada at clinical trial sites in Hamilton, Ottawa, and Halifax. Those eligible for participation must:

  • Have at least three doses of an mRNA COVID-19 vaccine
  • Have never received the AstraZeneca COVID-19 vaccine
  • Have not had a COVID-19 infection or COVID-19 vaccination within three months prior to enrollment
  • Have no diagnosis of lung disease
  • Be available to attend trial visits in-person
  • Be age 18-65

    • Smaill says that the study is a randomized placebo-controlled trial, noting that two-thirds of the study’s participants will receive the vaccine, while the other third will receive a placebo.

    Participants won’t know which group they belong to, but the researchers argue that both groups are equally integral to the study.


    Source link

    Search